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Background: Interleukin 17 (IL-17) is a proinflammatory cytokine produced mainly by CD4+ T-lymphocytes and
may be important in tumor cell growth and progression. In this study, we aimed to evaluate the diagnostic and
prognostic value of pleural effusion levels of IL-17 in lung cancer patients with malignant pleural effusion (MPE).
Methods: Pleural effusion samples were collected from 78 lung cancer patients with MPE and from 45 patients
with nonmalignant pleural effusion. Pleural fluid concentrations of IL-17 were measured by using enzyme-linked
immunosorbent assays.
Results: Malignant effusion exhibited higher IL-17 levels than nonmalignant effusion (20.49 ± 5.27 pg/ml vs.
13.16 ± 2.25 pg/ml; P < 0.01). Lung cancer patients with pleural fluid IL-17 levels below 15 pg/ml had longer overall
survival than those patients with higher levels (10.8 months vs. 4.7 months; P < 0.05). On the basis of multivariate
analysis, we found that pleural fluid IL-17 level was an independent prognostic factor in lung cancer patients with MPE.
Conclusions: Measurement of IL-17 levels might be a useful diagnostic and prognostic test for lung cancer patients
with MPE.Background
Lung cancer is the leading cause of cancer-related mor-
tality in the world [1]. Approximately 15% of lung cancer
patients have pleural effusion at the time of initial diagnosis,
and 50% develop it later in the course of their disease
[2]. Differentiating malignant from nonmalignant pleural
effusion is a critical problem, and conventional methods
have proven inadequate [3-6]. Pleural fluid cytology has
traditionally been the analytical method of choice for
the detection of tumor cells in pleural fluid. However,
sensitivity varies between 30% and 60% [7], and blindly
obtained pleural needle biopsy specimens offer little
additional sensitivity [8]. Although the presence of tumor
cells in pleural effusion is a diagnostic marker of malignant
pleural effusion (MPE), the probability of finding them
is low. For negative cytology pleural effusion, some of the
currently used indices, such as carcinoembryonic antigen,
neuron-specific enolase and cytokeratin 19 fragments
(CYFRA 21-1), have a certain extent of differential value;* Correspondence: yulike_doctor@163.com
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reproduction in any medium, provided the orhowever, their specificity and sensitivity are limited [9,10].
Therefore, searching for new indices is very important.
In addition to diagnostic issues, patients with MPE have
a poor prognosis and are difficult to treat effectively [11].
Despite advances in treatment modalities, the overall
survival (OS) is still very short. The present standard
treatment is to evacuate the pleural fluid, followed by
intravenous chemotherapy or intrapleural chemotherapy
[12]. However, it was found that not all patients were
benefited from the addition of chemotherapy, especially in
patients with short OS. Therefore, prognostic assessment
of the patient is essential. Hsu et al. proved that the
expression level of angiogenetic biomarkers was signifi-
cantly correlated with patient survival and pleural effusion
control [13]. In addition, researchers in recent molecular
and genetic profiling studies identified several markers as
diagnostic and prognostic factors of lung cancer.
The improved understanding of pleural effusion immu-
nopathogenesis could lead to the development of immu-
nodiagnostic tools to facilitate its differential diagnosis.
Investigators in large-scale studies have reported that
lymphocytes play an important role in the pathogenesisThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Patient characteristicsa
Variables MPE BPE P-value
Patients, n 78 45
Mean age (±SD), years 56.3 ± 12.5 55.6 ± 11.7 >0.05
Male/female 36/42 34/11 >0.05
MPE
Adenocarcinoma 67 ND
Squamous cell carcinoma 5 ND
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ated into interleukin 17 (IL-17)-producing T helper (Th17)
cells. Th17 cells produce unique cytokines, including
IL-17A, IL-17F and IL-22. These cytokines play a role in
inflammation and cancers [18-21]. In previous studies,
researchers have reported that the levels of IL-17 are
elevated in pleural effusion [22,23]. However, whether
there is a significant difference in their expression level
as well as in the relationship between pleural fluid IL-
17 concentrations and the prognosis for patients with
lung cancer have not been evaluated to date.
In our present study, we assessed pleural effusion of
various etiologies in 123 patients to determine whether
IL-17 pleural fluid could be used as a diagnostic indicator
of lung cancer and a predictor of survival time. We found
that IL-17 is elevated in malignant effusion caused by lung
cancer, as well as being potentially predictive of survival
outcome.Pleural biopsy 6 8
Percutaneous biopsy 12 4
Endoscopic examination 10 3
aBPE, Benign pleural effusion; MPE, Malignant pleural effusion; ND, No data.Methods
Patients
The study included 123 consecutive patients with pleural
effusion who were recruited from the Nanjing Chest
Hospital from January 2009 to December 2010. All cases
of pleural effusion had a definite etiology documented
by examination of effusion biochemistry, cytology, pleural
biopsy, percutaneous biopsy, endoscopic examination and
clinical follow-up. The characteristics of the patients are
summarized in Table 1. The patient group included 70
men and 53 women with a median age of 65 years. Of
the total sample, 78 patients (63.4%) had MPE and 45
(36.6%) had nonmalignant pleural effusion. The OS time
in patients with MPE was measured from the time of diag-
nosis to the date of death or the last follow-up.
This study was approved by the Ethics Committee of
Nanjing Chest Hospital, and informed consent was ob-
tained from each patient.Diagnostic criteria for pleural effusion
The diagnostic criteria for MPE were as follows. Cytological
evidence of malignant cells present in pleural effusion or in
biopsy specimens. Tuberculous (TB) pleural effusion was
diagnosed according to the following findings: identification
of acid-fast bacilli in pleural fluid, caseous granulomas in a
pleural biopsy specimen and a high level of pleural fluid
adenosine deaminase (>40 U/L) with an improvement
of the pleurisy after anti-TB therapy. Parapneumonic ef-
fusion was characterized by any pleural effusion associated
with pneumonia and response to antibiotics. Patients
with pleural empyema were also included in this group.
Effusions related to heart failure were collected from
patients with documented heart failure but without
neoplastic or other disease.Sample collection and determination of IL-17
concentration
Fresh pleural effusion specimens were collected before
treatment and centrifuged at 1,500 × g for 10 minutes
at −4°C. The supernatants were immediately stored
at −80°C until use. The IL-17 concentrations were deter-
mined by enzyme-linked immunosorbent assay (ELISA)
with the commercial human IL-17 Ready-SET-Go! ELISA
Kit (eBioscience, San Diego, CA, USA). All assays were
run in duplicate, with dilutions as appropriate, and the
technicians were blinded to clinical data.Statistical analyses
All statistical analyses of differences between malignant
effusions and nonmalignant pleural effusion were per-
formed using the Mann–Whitney U test. The diagnostic
accuracy of IL-17 in discriminating between lung cancer
with malignant and nonmalignant pleural effusion was
compared by constructing receiver operating characteristic
(ROC) curves. The optimum cutoff point from the ROC
analysis was established by selecting the value that provided
the greatest sum of sensitivity and specificity. Survival
analyses were performed using the Kaplan–Meier method,
and significant differences in survival rates were compared
using the logrank test. The Cox proportional hazards
regression model was used to compare the relative
influence of different prognostic factors. P < 0.05 was
considered to indicate statistical significance.
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Levels of IL-17 in pleural effusion
As shown in Figure 1, patients with malignant effusion
exhibited higher IL-17 concentration than those with
nonmalignant pleural effusion (20.49 ± 5.27 pg/ml vs.
13.16 ± 2.25 pg/ml; P = 0.004). Pleural fluid IL-17 concen-
trations in patients with malignant effusion were higher
than in patients with TB effusion (20.49 ± 5.27 pg/ml vs.
17.43 ± 5.39 pg/ml; P = 0.021).Diagnostic value of IL-17 in malignant pleural effusion
ROC curve analysis was carried out to assess the IL-17
concentrations in patients with MPE. The area under the
ROC curve was 0.724 (95% confidence interval = 0.635 to
0.812). The best efficacy was observed at 15 pg/ml. Using
a cutoff value of 15 pg/ml, IL-17 had a sensitivity of 79.5%
(62 of 78 patients), specificity of 91.1% (41 of 45 patients),
accuracy of 83.7% (103 of 123 patients), positive predictive
value of 93.9% (62 of 66 patients) and negative predictive
value of 71.9% (41 of 57 patients) (Figure 2).Relationship between IL-17 concentration and
clinicopathological factors in lung cancer patients with
malignant pleural effusion
After we confirmed that the IL-17 concentration was
elevated in patients with MPE, we sought possible rela-
tionships between IL-17 and gender, age, histologic type
of tumor, cancer stage, Eastern Cooperative Oncology
Group performance status (ECOG PS), positive cyto-
logic examination and location of pleural effusion. As
shown in Table 2, we found no significant correlation
between IL-17 concentration and any of these clinico-
pathological factors.Figure 1 Levels of interleukin 17 in pleural effusion. Malignant effusion
nonmalignant effusion and tuberculous effusion. *compared with nonmaligPrognostic significance of pleural fluid IL-17 for lung
cancer patients with malignant pleural effusion
The OS for all lung cancer patients in the current study
was 6.7 months, and the 1-year survival rate was 21.8%.
The prognostic significance of pleural fluid IL-17 con-
centration and other factors in patients with MPE was
evaluated by univariate analysis (Table 3). The cutoff value
chosen for pleural fluid IL-17 concentration in lung
cancer patients was 15 pg/ml. High pleural fluid IL-17
concentration, older age, late-stage disease and poor
ECOG PS were factors associated with poor survival.
The survival time in lung cancer patients with pleural
fluid IL-17 concentrations below 15 pg/ml was signifi-
cantly longer than in those with higher concentrations
(OS 10.8 vs. 4.7 months; P < 0.05) (Figure 3).
To test the prognostic value of pleural fluid IL-17 con-
centration, we performed multivariate analysis of prognos-
tic factors using the Cox proportional hazards model. We
found that pleural fluid IL-17 concentration (P = 0.007) had
independent prognostic significance, whereas ECOG PS
(P = 0.157), age (P = 0.545), tumor location (P = 0.362) and
cancer stage (P = 0.734) lacked significant independent
effects on survival (Table 4).
Discussion
To the best of our knowledge, this study is the first on
pleural effusion in which IL-17 levels were investigated
for their diagnostic and prognostic power simultaneously
in lung cancer patients with MPE. Our findings suggest
that profoundly elevated pleural fluid concentrations of
IL-17 (≥15 pg/ml) measured at the onset of effusion corre-
lated with shorter survival in lung cancer patients. Further-
more, multivariate analysis of prognostic factors identified
pleural fluid IL-17 concentration as an independent
prognostic factor for OS. These results suggest thatexhibited higher interleukin 17 (IL-17) concentrations than in
nant effusion group and TB effusion group, P < 0.05 for both.
Figure 2 Receiver operating characteristic curve of interleukin 17 for the differential diagnosis of malignant and nonmalignant effusion.
ROC, Receiver operating characteristic.
Table 2 Interleukin 17 levels in pleural effusion of lung
cancer patientsa




≥60 38 27.08 ± 4.87
<60 40 19.92 ± 5.28
Gender 0.259
Male 36 21.23 ± 5.30
Female 42 19.87 ± 5.23
Histologic type 0.491
Adenocarcinoma 67 20.33 ± 6.12
Nonadenocarcinoma 11 21.52 ± 5.05
ECOG PS 0.256
0 or 1 50 19.99 ± 5.37
2 to 4 28 21.41 ± 5.21
Cytologic examination 0.912
Positive 60 20.46 ± 5.18
Negative 18 20.62 ± 6.12
Stage 0.706
M1a 54 20.34 ± 4.58
M1b 24 20.83 ± 6.01
Location 0.751
Right 50 20.34 ± 5.36
Left 28 20.15 ± 4.97
aECOG PS, Eastern Cooperative Oncology Group performance status; IL-17,
Interleukin 17.
Table 3 Univariate analysis for overall survival in lung
cancer patients with malignant pleural effusiona











0 or 1 50 9.4










aECOG PS, Eastern Cooperative Oncology Group performance status; OS,
overall survival. *Significant difference.
Xu et al. European Journal of Medical Research 2014, 19:23 Page 4 of 6
http://www.eurjmedres.com/content/19/1/23
Figure 3 Relationship between pleural fluid interleukin 17 levels and overall survival in lung cancer patients analyzed by Kaplan–Meier
analysis. The survival of lung cancer patients with pleural fluid interleukin 17 (IL-17) levels <15 pg/ml was significantly longer than the survival of
patients with levels ≥15 pg/ml (P < 0.05).
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indicator of not only the presence of lung cancer but
also the patient’s survival outcome.
IL-17 is a proinflammatory cytokine produced mainly
by CD4+ T lymphocytes. It may be important in tumor
cell growth and may contribute to the aggressiveness ofTable 4 Multivariate Cox proportional hazards analysis for
overall survival in lung cancer patients with malignant
pleural effusiona
Parameters HR 95% CI P-value
Age (years) 0.545
≥60 1
<60 1.263 0.593 to 2.689
IL-17 (pg/ml) 0.007*
≥15 1
<15 0.329 0.146 to 0.742
ECOG PS 0.157
0 or 1 1
2 to 4 0.653 0.778 to 4.745
Location 0.362
Right 1
Left 0.455 0.083 to 2.479
Stage 0.734
M1a 1
M1b 0.168 0.449 to 3.112
a95% CI, 95% confidence interval; ECOG PS, Eastern Cooperative Oncology
Group performance status; HR, Hazard ratio; IL-17, Interleukin 17.
*Significant difference.human tumors [24]. Recently, accumulating evidence has
shown that IL-17-positive cells are frequently present in
multiple cancers, including prostate cancer [25], colorectal
cancer [26], hepatocellular carcinoma [27], breast cancer
[28], ovarian cancer [20] and non-small-cell lung cancer
[29]. Researchers in some studies have reported that IL-17
cell expression in MPE is elevated [15,23]. Most of the
reports indicate that IL-17 may protect against tumors
by promoting immune system–mediated tumor rejection
[30]. These results suggest the IL-17 plays an important
role in tumor immune system evasion. One inference
derived from this hypothesis is that IL-17 concentration
in pleural effusion could be a good indicator in the
follow-up of tumor patients, which is supported by our
presently reported results.
Differentiating malignant from nonmalignant pleural
effusion is a clinical problem, and conventional methods
have proven inadequate [3-6]. A reliable marker for
rapid and accurate diagnosis of pleural effusion is
greatly needed. In this study, the IL-17 concentrations
in malignant pleural effusion were higher than those
in nonmalignant and TB pleural effusion. Our results
suggest that IL-17 should be a tumor marker for the
diagnosis of MPE. No statistically significant correlation
was observed between IL-17 concentration and histo-
logical type of lung cancer. We assigned 15 pg/ml IL-17 in
MPE as the diagnostic cutoff value, which had sensitivity
of 79.5% and specificity of 91.1%. This result shows that
IL-17 concentration could be a valuable marker in the
differential diagnosis of malignant and nonmalignant
pleural effusion. Further studies of the potential efficacy
of this marker are needed.
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IL-17 concentrations in MPE associated with lung cancer
are significantly higher than those in nonmalignant pleural
effusion. Determination of IL-17 concentration in pleural
effusion is diagnostically informative and IL-17 concen-
tration is an independent prognostic factor that shows
promise in the follow-up of lung cancer patients who
develop pleural effusion.
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